Beam TherapeuticsのROIC
Beam TherapeuticsのROICは何ですか。
Beam Therapeutics Inc.のROICは-9.36%です。
ROICの定義は何ですか。
Return on invested capital (ROIC) is a financial ratio that measures how efficient a company is at allocating the capital under its control to profitable investments.
= NOPAT / Invested capital = EBIT * (1 - tax rate) / (2-year average liabilities + 2-year average shareholder equity)
Return on invested capital (ROIC) ratio gives investors a sense of how well a company is using money under its control to generate profitable returns.
ROIC can be used as a benchmark to calculate the valuation of companies across industries. A higher ROIC means the company is doing a better job of investing the money from shareholders and bondholders to run the business. A company is creating value if its ROIC exceeds 2%. If its ROIC is under 2%, the company is likely destroying value and has no excess capital to invest in future growth.
You can calculate ROIC with the following formula:
NOPAT = Net operating profit after tax
Invested Capital = Average total liabilities + Average shareholders' equity
The averages of liabilities and shareholders' equity are calculated as geometrical averages of the last two annual values from the company's balance sheet.
NASDAQのセクタHealth CareにおけるROICの企業と比べるBeam Therapeutics
Beam Therapeuticsは何をしますか。
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeuticsと類似のroic
- CryoPort IncのROICは-9.40%です。
- Pacific Drilling SAのROICは-9.39%です。
- FuelCellのROICは-9.39%です。
- MBIAのROICは-9.39%です。
- BlackRock Utility Infrastructure & Power Opportunities TrustのROICは-9.38%です。
- Childrens Place IncのROICは-9.37%です。
- Beam TherapeuticsのROICは-9.36%です。
- iQIYIのROICは-9.35%です。
- The Original BARKのROICは-9.34%です。
- ArcotechのROICは-9.34%です。
- AwoX SAのROICは-9.33%です。
- Arrow GreentechのROICは-9.32%です。
- Illumina IncのROICは-9.30%です。